Protocol for Desensitization to Trastuzumab in a Patient With Anaphylaxis and Stage IV Breast Cancer: A Case Report

J Investig Allergol Clin Immunol. 2020;30(5):376-377. doi: 10.18176/jiaci.0558. Epub 2020 May 6.

Authors

C E de Lira-Quezada¹, R V Villarreal-González¹, S N González-Díaz¹, N Acuña-Ortega¹

Affiliation

¹ Regional Center of Allergy and Clinical Immunology, University Hospital "Dr. José Eleuterio González", Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.

PMID: 32376514
DOI: 10.18176/jiaci.0558

No abstract available

Keywords: Anaphylaxis; Biologic therapy; Desensitization; Trastuzumab.

Publication types

Case Reports

MeSH terms

Anaphylaxis / diagnosis
Anaphylaxis / etiology*
Anaphylaxis / therapy*
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Breast Neoplasms / complications*
Breast Neoplasms / diagnosis
Breast Neoplasms / drug therapy
Desensitization, Immunologic* / methods
Drug Hypersensitivity / diagnosis
Drug Hypersensitivity / etiology
Drug Hypersensitivity / therapy
Female
Humans
Middle Aged
Molecular Targeted Therapy / adverse effects
Neoplasm Staging
Skin Tests
Symptom Assessment
Trastuzumab / adverse effects*
Trastuzumab / therapeutic use

Substances

Antineoplastic Agents, Immunological
Trastuzumab